Our study uncovered a novel molecular mechanism of lncRNA SNHG4 in driving prostate cancer progression and enzalutamide resistance, revealing the critical roles and therapeutic potential of RREB1, SNHG4 and let-7 miRNAs in anticancer therapy. The gene discussed is RREB1; the disease is Familial prostate cancer.